Is IMA or FULC more profitable?

Fulcrum Therapeutics' return on equity of -27.80% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.96% -34.60% Fulcrum Therapeutics N/A -27.80% -26.32%

Which has better earnings & valuation, IKT or IMA?

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibikase Therapeutics N/A N/A -$48.26M -$0.43 N/A ImageneBio N/A N/A -$45.35M -$5.79 N/A

Is IKT or IMA more profitable?

ImageneBio's return on equity of -38.96% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% ImageneBio N/A -38.96% -34.60%

Which has higher valuation & earnings, ALXO or IMA?

ALX Oncology is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A ImageneBio N/A N/A -$45.35M -$5.79 N/A

Is ALXO or IMA more profitable?

ImageneBio's return on equity of -38.96% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% ImageneBio N/A -38.96% -34.60%

ImageneBio (IMA) Competitors

$6.00 -0.01 (-0.17%)

Closing price 04:00 PM Eastern

Extended Trading

$6.00 +0.00 (+0.08%)

As of 04:10 PM Eastern

Compare

IMA vs. FULC, IKT, FHTX, ALXO, and FATE

Should you buy ImageneBio stock or one of its competitors? MarketBeat compares ImageneBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImageneBio include Fulcrum Therapeutics (FULC), Inhibikase Therapeutics (IKT), Foghorn Therapeutics (FHTX), ALX Oncology (ALXO), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry.

How does ImageneBio compare to Fulcrum Therapeutics?

ImageneBio (NASDAQ:IMA) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Fulcrum Therapeutics' return on equity of -27.80% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ImageneBio has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.93, indicating that its share price is 193% more volatile than the broader market.

ImageneBio presently has a consensus price target of $26.50, suggesting a potential upside of 341.67%. Fulcrum Therapeutics has a consensus price target of $8.20, suggesting a potential upside of 118.09%. Given ImageneBio's stronger consensus rating and higher possible upside, analysts clearly believe ImageneBio is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

ImageneBio has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	N/A	N/A	-$45.35M	-$5.79	N/A
Fulcrum Therapeutics	$80M	3.13	-$74.88M	-$1.15	N/A

In the previous week, Fulcrum Therapeutics had 3 more articles in the media than ImageneBio. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 0 mentions for ImageneBio. Fulcrum Therapeutics' average media sentiment score of 0.10 beat ImageneBio's score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ImageneBio	Neutral
Fulcrum Therapeutics	Neutral

Summary

Fulcrum Therapeutics beats ImageneBio on 10 of the 15 factors compared between the two stocks.

How does ImageneBio compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and ImageneBio (NASDAQ:IMA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A
ImageneBio	N/A	N/A	-$45.35M	-$5.79	N/A

In the previous week, Inhibikase Therapeutics' average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
ImageneBio	Neutral

Inhibikase Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

ImageneBio's return on equity of -38.96% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
ImageneBio	N/A	-38.96%	-34.60%

Inhibikase Therapeutics currently has a consensus price target of $5.40, indicating a potential upside of 188.77%. ImageneBio has a consensus price target of $26.50, indicating a potential upside of 341.67%. Given ImageneBio's higher possible upside, analysts clearly believe ImageneBio is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Summary

Inhibikase Therapeutics and ImageneBio tied by winning 6 of the 12 factors compared between the two stocks.

How does ImageneBio compare to Foghorn Therapeutics?

ImageneBio (NASDAQ:IMA) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

ImageneBio has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are held by institutional investors. 2.2% of ImageneBio shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ImageneBio presently has a consensus target price of $26.50, suggesting a potential upside of 341.67%. Foghorn Therapeutics has a consensus target price of $11.43, suggesting a potential upside of 180.11%. Given ImageneBio's higher probable upside, analysts plainly believe ImageneBio is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Foghorn Therapeutics had 2 more articles in the media than ImageneBio. MarketBeat recorded 2 mentions for Foghorn Therapeutics and 0 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.00 beat Foghorn Therapeutics' score of -0.31 indicating that ImageneBio is being referred to more favorably in the media.

Company	Overall Sentiment
ImageneBio	Neutral
Foghorn Therapeutics	Neutral

ImageneBio has higher earnings, but lower revenue than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	N/A	N/A	-$45.35M	-$5.79	N/A
Foghorn Therapeutics	$28.22M	8.49	-$74.28M	-$1.16	N/A

ImageneBio has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, indicating that its share price is 189% more volatile than the broader market.

Summary

Foghorn Therapeutics beats ImageneBio on 8 of the 15 factors compared between the two stocks.

How does ImageneBio compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

ImageneBio's return on equity of -38.96% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
ImageneBio	N/A	-38.96%	-34.60%

ALX Oncology presently has a consensus target price of $4.60, indicating a potential upside of 156.98%. ImageneBio has a consensus target price of $26.50, indicating a potential upside of 341.67%. Given ImageneBio's higher possible upside, analysts plainly believe ImageneBio is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

ALX Oncology has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

ALX Oncology is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
ImageneBio	N/A	N/A	-$45.35M	-$5.79	N/A

In the previous week, ALX Oncology's average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score.

Company	Overall Sentiment
ALX Oncology	Neutral
ImageneBio	Neutral

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

ImageneBio beats ALX Oncology on 7 of the 12 factors compared between the two stocks.

How does ImageneBio compare to Fate Therapeutics?

ImageneBio (NASDAQ:IMA) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

ImageneBio has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.53, suggesting that its share price is 153% more volatile than the broader market.

In the previous week, Fate Therapeutics had 1 more articles in the media than ImageneBio. MarketBeat recorded 1 mentions for Fate Therapeutics and 0 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.00 equaled Fate Therapeutics'average media sentiment score.

Company	Overall Sentiment
ImageneBio	Neutral
Fate Therapeutics	Neutral

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ImageneBio has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. ImageneBio's return on equity of -38.96% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

ImageneBio currently has a consensus target price of $26.50, indicating a potential upside of 341.67%. Fate Therapeutics has a consensus target price of $5.13, indicating a potential upside of 148.79%. Given ImageneBio's higher possible upside, analysts clearly believe ImageneBio is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

ImageneBio has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	N/A	N/A	-$45.35M	-$5.79	N/A
Fate Therapeutics	$6.65M	36.11	-$136.32M	-$1.09	N/A

Summary

Fate Therapeutics beats ImageneBio on 8 of the 15 factors compared between the two stocks.

Get ImageneBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMA vs. The Competition

Export

Metric	ImageneBio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$63.92M	$3.51B	$6.56B	$12.24B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	-1.04	20.68	25.17	23.98
Price / Sales	N/A	336.69	553.76	120.62
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.50	8.26	10.76	6.41
Net Income	-$45.35M	$23.91M	$3.56B	$337.14M
7 Day Performance	5.45%	3.05%	1.37%	-0.48%
1 Month Performance	7.91%	2.40%	0.81%	0.49%
1 Year Performance	-63.50%	56.35%	30.53%	28.16%

ImageneBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMA ImageneBio	1.7548 of 5 stars	$6.00 -0.2%	$26.50 +341.7%	-62.6%	$63.92M	N/A	N/A	70	Gap Down
FULC Fulcrum Therapeutics	2.643 of 5 stars	$3.76 -2.2%	$8.20 +117.9%	-46.3%	$250.80M	$80M	N/A	100
IKT Inhibikase Therapeutics	1.6398 of 5 stars	$1.87 -0.3%	$5.40 +189.5%	N/A	$246.24M	N/A	N/A	6	Positive News
FHTX Foghorn Therapeutics	2.4059 of 5 stars	$4.10 -1.0%	$11.43 +178.9%	-15.3%	$241.90M	$28.22M	N/A	120	Analyst Downgrade Gap Up
ALXO ALX Oncology	2.2232 of 5 stars	$1.81 +2.6%	$4.60 +154.8%	+282.9%	$241.81M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMA) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImageneBio (IMA) Competitors

IMA vs. FULC, IKT, FHTX, ALXO, and FATE

How does ImageneBio compare to Fulcrum Therapeutics?

Summary

How does ImageneBio compare to Inhibikase Therapeutics?

Summary

How does ImageneBio compare to Foghorn Therapeutics?

Summary

How does ImageneBio compare to ALX Oncology?

Summary

How does ImageneBio compare to Fate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImageneBio (IMA) Competitors

IMA vs. FULC, IKT, FHTX, ALXO, and FATE

How does ImageneBio compare to Fulcrum Therapeutics?

Is IMA or FULC more profitable?

Do insiders and institutionals have more ownership in IMA or FULC?

Which has more volatility and risk, IMA or FULC?

Do analysts recommend IMA or FULC?

Which has preferable earnings and valuation, IMA or FULC?

Does the media favor IMA or FULC?

Summary

How does ImageneBio compare to Inhibikase Therapeutics?

Do insiders & institutionals have more ownership in IKT or IMA?

Which has better earnings & valuation, IKT or IMA?

Does the media refer more to IKT or IMA?

Which has more volatility & risk, IKT or IMA?

Is IKT or IMA more profitable?

Do analysts prefer IKT or IMA?

Summary

How does ImageneBio compare to Foghorn Therapeutics?

Is IMA or FHTX more profitable?

Do institutionals and insiders believe in IMA or FHTX?

Do analysts rate IMA or FHTX?

Does the media favor IMA or FHTX?

Which has better earnings & valuation, IMA or FHTX?

Which has more risk & volatility, IMA or FHTX?

Summary

How does ImageneBio compare to ALX Oncology?

Is ALXO or IMA more profitable?

Do analysts prefer ALXO or IMA?

Which has more risk and volatility, ALXO or IMA?

Which has higher valuation & earnings, ALXO or IMA?

Does the media refer more to ALXO or IMA?

Do insiders and institutionals hold more shares of ALXO or IMA?

Summary

How does ImageneBio compare to Fate Therapeutics?

Which has more risk and volatility, IMA or FATE?

Does the media prefer IMA or FATE?

Do insiders & institutionals believe in IMA or FATE?

Is IMA or FATE more profitable?

Do analysts rate IMA or FATE?

Which has better valuation and earnings, IMA or FATE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools